Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Processa is a clinical-stage biopharmaceutical company developing a pipeline of "Next Generation Cancer" (NGC) therapies. The company's strategy involves modifying existing, highly toxic cancer drugs (such as capecitabine, gemcitabine, and irinotecan) to improve their safety and efficacy profiles by altering their metabolism or distribution within the body. The company has no commercial products and generates no revenue.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11,850,118) | $(11,121,520) |
| Operating Expenses | $12,051,206 | $11,457,061 |
| Research & Development (R&D) | $7,269,146 | $5,799,518 |
| General & Administrative (G&A) | $4,782,060 | $5,657,543 |
| Cash and Cash Equivalents (Year End) | $1,191,325 | $4,706,197 |
| Accumulated Deficit | $(87,219,199) | $(75,369,081) |
| Net Cash Used in Operating Activities | $(11,245,042) | $(8,063,346) |
Note: The filing text does not provide specific debt figures other than lease liabilities. The company has no long-term debt.
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses increased by approximately $1.5 million (25%) year-over-year. This was primarily driven by costs associated with the Phase 1B trial for NGC-Cap and the initiation of the Phase 2 trial for NGC-Cap in breast cancer.
- Decreased G&A Spend: G&A expenses decreased by approximately $0.9 million (15%), largely due to a reduction in professional fees and stock-based compensation, partially offset by increased salaries.
- Cash Burn: Net cash used in operating activities increased by approximately $3.2 million compared to 2023, reflecting the accelerated clinical trial activities.
- Financing Activity: During 2024, the company raised approximately $7.8 million in net proceeds through a public offering and an At-The-Market (ATM) offering. In January 2025 (subsequent event), the company raised an additional $4.5 million in net proceeds.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management does not provide specific financial guidance. Based on cash on hand at year-end ($1.2 million) and the $4.5 million raised in January 2025, the company believes it has sufficient capital to fund operations into mid-2025. Additional financing will be required to continue development of NGC-Cap, NGC-Gem, and NGC-Iri.
Key Clinical Developments
- NGC-Cap (PCS6422): Phase 1B trial completed in early 2024. Phase 2 trial in advanced/metastatic breast cancer initiated in October 2024 with the first patient dosed.
- NGC-Gem (PCS3117): Completed Phase 2A trial in pancreatic cancer showing progression-free survival in 31% of patients.
- NGC-Iri (PCS11T): Preclinical studies show improved tumor-to-muscle ratio compared to standard irinotecan. Pre-IND studies planned for 2025.
Risks and Contingencies
- Going Concern: The company has incurred recurring losses and has an accumulated deficit of $87.2 million. The auditor has included an emphasis of matter paragraph regarding substantial doubt about the company's ability to continue as a going concern without additional financing.
- License Litigation: The company is in active litigation with Elion Oncology, Inc. regarding the termination of the license agreement for NGC-Cap. Elion purported to terminate the agreement in May 2024; Processa disputes this and has filed a counterclaim. Termination of this license would be materially adverse.
- Stock Listing: The company received notice from Nasdaq in February 2025 regarding non-compliance with the $1.00 minimum bid price requirement. It has 180 days to regain compliance or face delisting.
- Other Litigation: Two investors filed a lawsuit in December 2024 alleging fraud and negligent misrepresentation regarding a 2021 private offering.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $4.5 million raised in January 2025 to fund the Phase 2 trial of NGC-Cap through mid-2025 and the timeline for the next capital raise.
- Elion Litigation Status: Monitor the progress of the lawsuit with Elion Oncology, as the outcome determines the company's right to develop its lead asset, NGC-Cap.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement by August 4, 2025, to avoid delisting.
- Phase 2 Interim Data: Watch for the interim analysis results of the NGC-Cap Phase 2 trial, which will occur after 20 patients are treated.
- License Milestones: Review the diligence milestones in license agreements with Ocuphire and Yuhan, as the company noted it has not met certain deadlines and is seeking extensions.